The study, published in BMC Infectious Diseases by Yuan Xu, Christopher Naugler, and Deirdre Church of the University of Calgary and Alberta Precision Laboratories, took advantage of a rare structural feature of Canadian health care: a single, centralized laboratory system serving an entire province. Because essentially every clinically significant Fusobacterium culture in Alberta between 2012 and 2020 passed through provincial laboratories, the researchers could assemble a complete census of laboratory-confirmed infections across a defined population of roughly four million people. They linked those microbiology records to administrative health databases and supplemented the analysis with chart reviews, then applied multivariable logistic regression to disentangle which patient and microbial characteristics independently predicted the most dangerous outcome: bloodstream infection.

The headline numbers are sobering in their consistency. Over the nine-year study window, 298 patients with confirmed Fusobacterium infections were identified, a median age of 52.5 years, with women making up 37.9 percent of cases. The annual incidence hovered in a narrow band between 0.61 and 1.03 cases per 100,000 population, never spiking or collapsing across the decade. That stability is itself informative, suggesting that Fusobacterium disease is an endemic, steady background burden rather than an epidemic threat. But the age stratification told a more dramatic story: incidence climbed relentlessly with age, reaching 3.28 per 100,000 among people aged 80 and older, more than five times the provincial average.

Half of all infections turned serious. Bloodstream invasion occurred in 50.3 percent of the 298 cases, a striking proportion for an organism often dismissed as a contaminant or a minor oral commensal. When the researchers ran their regression models, four independent predictors of bloodstream infection emerged. A heavier burden of chronic illness, measured by the Charlson Comorbidity Index, nearly quintupled the odds, with an odds ratio of 4.80. Substance use more than doubled the odds at 2.73. And the identity of the infecting species mattered enormously: F. nucleatum carried an odds ratio of 2.65, while F. necrophorum carried an odds ratio of 16.39, by far the strongest signal in the entire analysis.

That species-level divide is the conceptual heart of the paper. Fusobacterium nucleatum accounted for 68.1 percent of all infections, making it the dominant clinical species, while F. necrophorum contributed 15.4 percent. Yet their epidemiological profiles could hardly be more different. F. nucleatum behaved like a classic opportunistic pathogen: infections with this species were independently associated with older age, with each additional year of age nudging the odds up slightly at an odds ratio of 1.01, with greater comorbidity burden at an odds ratio of 2.51, and with inpatient rather than outpatient encounters at an odds ratio of 2.33. In other words, F. nucleatum tends to strike people whose defenses are already compromised, typically within hospital walls.

F. necrophorum tells the opposite story. This species was the engine behind Lemierre’s syndrome, the rare but feared condition in which a seemingly ordinary throat infection seeds the internal jugular vein, producing septic thrombophlebitis and metastatic abscesses that can scatter through the lungs, joints, and other organs. In the Alberta cohort, Lemierre’s syndrome occurred in 5.7 percent of all Fusobacterium infections, and it struck primarily young people, with a median age of just 18 years, almost always in association with F. necrophorum. The contrast is stark: the same genus that quietly exploits the comorbidities of the elderly is also capable of felling a healthy teenager with a sore throat that spirals into a life-threatening vascular infection.

Technically, the study’s strength lies in its methodology. Identifying anaerobic organisms like Fusobacterium to the species level requires modern tools, and the Alberta laboratories relied on matrix-assisted laser desorption ionization–time of flight mass spectrometry, or MALDI-TOF, supplemented where necessary by 16S ribosomal RNA sequencing. This matters because older studies that lumped all Fusobacterium isolates together may have obscured exactly the species-specific patterns that this cohort exposes. By linking laboratory data to provincial administrative records, the researchers could also capture comorbidities, substance use, and health care encounters systematically rather than relying on the patchy documentation of individual charts alone, although chart reviews were used to verify clinical details.

The findings carry practical weight for clinicians. A patient growing Fusobacterium from a blood culture should not be treated as a curiosity; in this cohort, half of all infections reached the bloodstream, and the species identified in the laboratory carries real prognostic information. F. necrophorum in a young patient should raise immediate concern for Lemierre’s syndrome and prompt evaluation of the jugular venous system, while F. nucleatum in an older patient with a high Charlson score signals an opportunistic process that warrants a search for the underlying portal of entry, which in other literature has ranged from dental disease and sinus infections to colorectal lesions. The authors argue that species-level identification and an honest assessment of host factors, including substance use and cumulative comorbidity, are essential for meaningful risk stratification.

Beyond the clinic, the study feeds a broader scientific conversation. F. nucleatum has become one of the most intensively studied bacteria in cancer biology, with work on its Fap2 adhesin, its ability to promote epithelial-mesenchymal transition, and its enrichment within colorectal tumors drawing intense interest. This cohort study does not address oncogenesis directly, but it does something equally valuable: it establishes the baseline epidemiology of a pathogen whose cancer associations have sometimes outpaced our understanding of its ordinary infectious behavior. Knowing that F. nucleatum infections cluster in older, comorbid, hospitalized patients provides a population-level context against which the cancer hypotheses can be calibrated.

The study also has limitations worth noting. It is retrospective in design, relying on cultures that were ordered by treating physicians, so infections never tested will have escaped the census, and culture-negative disease is a known problem for fastidious anaerobes. The incidence figures therefore likely represent a floor rather than a ceiling. Still, within the limits of laboratory-confirmed disease, the picture is coherent and internally consistent across nine years. For a genus that spends most of its existence as a quiet member of the oral microbiome, Fusobacterium has now been given a proper epidemiological portrait: an uncommon but persistent cause of serious infection, splitting its clinical personality between the old and the young, the comorbid and the previously healthy, and rewarding any laboratory that bothers to identify it beyond the genus level.

Subject of Research: Population-based epidemiology and risk factors of Fusobacterium infections in Alberta, Canada

Article Title: Incidence and factors associated with fusobacterium infection: prospective from a population-based cohort study

Article References: Xu, Y., Naugler, C., & Church, D. (2026). Incidence and factors associated with fusobacterium infection: prospective from a population-based cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14596-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14596-6

Keywords: Fusobacterium, F. nucleatum, F. necrophorum, bloodstream infection, Lemierre's syndrome, epidemiology, risk factors, anaerobic bacteria, cohort study, MALDI-TOF, Charlson Comorbidity Index, infectious diseases